UK Leaders: Gilead’s Hilary Hutton-Squire on building trust with the NHSAs general manager of Gilead UK and Ireland, Hilary Hutton-Squire has been at the forefront of bringing several Share XUK Leaders: Gilead’s Hilary Hutton-Squire on building trust with the NHShttps://pharmaphorum.com/views-analysis-sales-marketing/uk-leaders-gilead-hilary-hutton-squire-on-building-trust-with-the-nhs/
Pharma industry body urges “ambition” in UK-EU trade talksA pharma industry group has welcomed the UK’s priorities in trade talks due to start with the EU Share XPharma industry body urges “ambition” in UK-EU trade talkshttps://pharmaphorum.com/market-access-2/pharma-industry-body-urges-ambition-in-uk-eu-trade-talks/
Dutch biotech sector feel benefits of EMA move, says industry leaderThe Netherlands’ biotech sector has already seen an upswing following the relocation of the European Medicines Agency (EMA) Share XDutch biotech sector feel benefits of EMA move, says industry leaderhttps://pharmaphorum.com/news/dutch-biotech-feeling-benefits-of-ema-relocation-says-industry-leader/
Sanofi Genzyme UK medical boss Marc Moodley discusses oncology plans, NICE and BrexitMarc Moodley has worked at Sanofi since 2018 and is the new medical head, UK and Ireland for Share XSanofi Genzyme UK medical boss Marc Moodley discusses oncology plans, NICE and Brexithttps://pharmaphorum.com/views-analysis-oncology/sanofi-genzyme-uk-medical-boss-marc-moodley-discusses-oncology-plans-nice-and-brexit/
Future proofing the UK’s research ecosystem in the face of global changeThe UK is a powerhouse of clinical research but maintaining that leading position – and all the benefits Share XFuture proofing the UK’s research ecosystem in the face of global changehttps://pharmaphorum.com/r-d/views-analysis-r-d/future-proofing-the-uks-research-ecosystem-in-the-face-of-global-change/
Nine for 2019: how did we do on our predictions, and what does this mean for 2020?Year-ends prompt reflection, both on what’s happened in the last 12 months and on the year ahead. At Share XNine for 2019: how did we do on our predictions, and what does this mean for 2020?https://pharmaphorum.com/views-and-analysis/nine-for-2019-2020/
Corbyn pledges to create state-run generics firm to cut drug pricesLabour leader Jeremy Corbyn has included in the party’s election manifesto plans to create a state-run generic drug Share XCorbyn pledges to create state-run generics firm to cut drug priceshttps://pharmaphorum.com/news/corbyn-pledges-to-create-state-run-generics-firm-to-cut-drug-prices/
Secret US-UK talks on drug pricing revealedDespite the UK still not leaving the European Union – pencilled in for the 31 January 2020 at Share XSecret US-UK talks on drug pricing revealedhttps://pharmaphorum.com/views-analysis-market-access/secret-us-uk-talks-on-drug-pricing-revealed/
Rare disease patients unconvinced by health secretary’s post-Brexit research plansThe UK health secretary has responded to an open letter from rare disease patients, raising concerns about the Share XRare disease patients unconvinced by health secretary’s post-Brexit research planshttps://pharmaphorum.com/news/rare-disease-patients-unconvinced-by-health-secretarys-post-brexit-rd-plans/
